The consolidation was done to meet Nasdaq requirements (and yes to raise money and dual list, both of which are good things in this environment IMO).
I know ADRs and ADSs can be used for dual listings (pros and cons for these avenues that deserve a much longer discussion), but that clearly just isn't what's happening.
It's a straight up Nasdaq full security share issue deal on the table, so the consolidation was 100% needed under those terms.
Raising money and making the price attractive to potential investors is pretty much what's always needed, so I don't see a problem here.
I've got huge respect for you amb005, but getting hung up on the necessary consolidation seems counter productive. Your examples of past negative performance from other companies who have consolidated shares remain valid, but the liquidity issues you're talking about also work both ways - till the book settles, the SP can move up as much as down with the same kind of volatility. Still the same supply demand pressures at play.
Ultimately, for me like in any investment, it all still comes down to the fundamentals of the company in the long term, and with the ongoing validation of NanoCelle IP, NanaBis heading to P3, partnerships and royalties building, and a balance sheet with circa $8-9m cash and receivables, plus a big ($20m+?) cash injection from the listing, the share price will adjust accordingly in due course.
I used to talk a lot with an investor who would only look at penny dreadful stocks, because $10 stocks were "too expensive". Thing is, the nominal price of a stock is an utterly irrelevant number; it means absolutely nothing outside of SOIxSP=MC & fundamentals, and in the short term, market emotional perception. Put $100k into a 10c stock or a $10 stock, if it goes up 30%, you make the same profit. I know you know this.
Savvy management may want to release good news, but also can't make it up exactly when the timing suits them. Also, I personally wouldn't drop any news until the code was back under MDC and the book rebuild was settled, otherwise you risk wasting news and confusing potential new investors.
Just my opinion, GLTAH and DYOR
- Forums
- ASX - By Stock
- MDC
- Ann: UNSW Medlab Laboratory Collaboration Additional Information
Ann: UNSW Medlab Laboratory Collaboration Additional Information, page-23
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MDC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.60 |
Change
0.000(0.00%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MDC (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online